Add Yahoo as a preferred source to see more of our stories on Google. Lecanemab is the first novel treatment for Alzheimer's in more than 20 years Lecanemab, the disease-modifying drug which can slow ...

Please provide your email address to receive an email when new articles are posted on . Lecanemab led to more infusion reactions than in CLARITY-AD clinical trial. Patients had lower ARIA rates in ...

BioArctic's AB (publ) (NASDAQ: BIOA B) partner Eisai presented new data at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™), held ...

The experimental drug lecanemab shows "potential" as an Alzheimer's disease treatment, according to new Phase 3 trial results, but the findings raise some safety concerns because of its association ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Lecanemab led to a 44% reduction of biomarker ...

A "boot camp" session at the American Academy of Neurology (AAN) annual meeting focused on the logistical challenges of prescribing lecanemab (Leqembi) for Alzheimer's disease, including how to select ...

Researchers have developed a novel compound that could transform the way we treat Alzheimer's disease, offering not just a ...

The research team examined data on the health status of 2,672 patients 28 weeks after the start of the treatment.

NHS watchdog to review evidence on two pioneering Alzheimer’s drugs - Donanemab and lecanemab were licensed for use in the UK in 2024 but were not made available on the NHS after Nice deemed their ben ...

LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option The BLA is based on data from the ...

A medication that could help treat early stages of Alzheimer's disease is on track to be approved for manufacturing and sales ...